Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Remdesivir  COVID-19 treatment studies for Remdesivir  C19 studies: Remdesivir  Remdesivir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Recovery time -75% Improvement Relative Risk Hospitalization time -56% Time to viral- -61% c19early.org/s Ong et al. Remdesivir for COVID-19 EARLY TREATMENT Is early treatment with remdesivir beneficial for COVID-19? Retrospective 18 patients in Singapore Slower recovery (p=0.6) and longer hospitalization (p=0.31), not stat. sig. Ong et al., Acta Oncologica, doi:10.1080/0284186X.2023.2169079 Favors remdesivir Favors control

A cohort study of COVID-19 infection in pediatric oncology patients plus the utility and safety of remdesivir treatment

Ong et al., Acta Oncologica, doi:10.1080/0284186X.2023.2169079
Ong et al., A cohort study of COVID-19 infection in pediatric oncology patients plus the utility and safety of remdesivir.., Acta Oncologica, doi:10.1080/0284186X.2023.2169079
Jan 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 18 immunocompromised pediatric COVID-19 patients in Singapore, showing slower viral clearance with remdesivir, without statistical significance.
[Gérard, Wu, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
recovery time, 75.0% higher, relative time 1.75, p = 0.60, treatment 4, control 14, defervescence.
hospitalization time, 55.6% higher, relative time 1.56, p = 0.31, treatment 4, control 14.
time to viral-, 60.7% higher, relative time 1.61, p = 0.14, treatment 4, control 14.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ong et al., 20 Jan 2023, retrospective, Singapore, peer-reviewed, 12 authors.
Contact: rina.ong.yl@kkh.com.sg, yung.chee.fu@singhealth.com.sg.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperRemdesivirAll
Abstract: Acta Oncologica ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/ionc20 A cohort study of COVID-19 infection in pediatric oncology patients plus the utility and safety of remdesivir treatment Rina Yue Ling Ong, Valerie Xue Fen Seah, Chia Yin Chong, Koh Cheng Thoon, Natalie Woon Hui Tan, Jiahui Li, Karen Donceras Nadua, Shui Yen Soh, Michaela Su-Fern Seng, Thi Ngoc Anh Pham, Chee Fu Yung & Kai-Qian Kam To cite this article: Rina Yue Ling Ong, Valerie Xue Fen Seah, Chia Yin Chong, Koh Cheng Thoon, Natalie Woon Hui Tan, Jiahui Li, Karen Donceras Nadua, Shui Yen Soh, Michaela Su-Fern Seng, Thi Ngoc Anh Pham, Chee Fu Yung & Kai-Qian Kam (2023) A cohort study of COVID-19 infection in pediatric oncology patients plus the utility and safety of remdesivir treatment, Acta Oncologica, 62:1, 53-57, DOI: 10.1080/0284186X.2023.2169079 To link to this article: https://doi.org/10.1080/0284186X.2023.2169079 Published online: 20 Jan 2023. Submit your article to this journal Article views: 470 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=ionc20 ACTA ONCOLOGICA 2023, VOL. 62, NO. 1, 53–57 https://doi.org/10.1080/0284186X.2023.2169079 LETTER TO THE EDITOR A cohort study of COVID-19 infection in pediatric oncology patients plus the utility and safety of remdesivir treatment Rina Yue Ling Onga , Valerie Xue Fen Seaha , Chia Yin Chongb,c,d,e , Koh Cheng Thoonb,c,d,e , Natalie Woon Hui Tanb,c,d,e , Jiahui Lib,c,d,e, Karen Donceras Naduab,c,d,e , Shui Yen Sohc,d,e,f , Michaela Su-Fern Sengc,d,e,f , Thi Ngoc Anh Phamg, Chee Fu Yungb,d,e and Kai-Qian Kamb,c,d,e a Department of Pharmacy, KK Women’s and Children’s Hospital, Singapore, Singapore; bInfectious Disease Service, Department of Pediatrics, KK Women’s and Children’s Hospital, Singapore, Singapore; cYong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; dDuke-National University of Singapore Medical School, Singapore, Singapore; eLee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore; fHaematology/Oncology Service, Department of Pediatrics, KK Women’s and Children’s Hospital, Singapore, Singapore; gNursing Clinical Services, Division of Nursing, KK Women’s and Children’s Hospital, Singapore, Singapore ARTICLE HISTORY Received 22 November 2022; Accepted 11 January 2023
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit